Ohman Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ohman Kwon has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Mi-Young Son
Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea
8 shared publications - Dae-Soo Kim
Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea
7 shared publications - Hana Lee
Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea
7 shared publications - Hyun-Soo Cho
Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea
6 shared publications Won Dong Yu
Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea
5 shared publications- Kwang Bo Jung
Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58  (7) , 2223-2234
Sphingosine-1-phosphate receptor 1 signaling stimulates human pluripotent stem cell-derived cardiomyocyte differentiation and maturation
The development of human-relevant in vitro cardiac models is essential for evaluating cardiotoxicity and drug efficacy. Although wingless-related integration site signaling-based protocols have enabled cardiomyocyte (CM) differentiation from pluripotent stem cells, issues such as low efficiency, immature phenotype, and variability across cell lines remain to be resolved. Here, we present an improved differentiation strategy that robustly enhances both the efficiency and functional maturity of CMs, comparable to the functional characteristics of human adult myocardial tissue. Although fetal bovine serum enhanced differentiation, we disclosed that the interaction between sphingosine-1-phosphate (S1P) and its receptor S1PR1 is a major contributor. Gene-based and protein-based analyses and electrophysiological analysis via multielectrode array confirmed that activation of S1PR1 using S1P or its agonist SEW2871 increased the generation of spontaneously beating CMs, whereas S1PR1-deficient pluripotent stem cells exhibited impaired differentiation and functional maturity of S1P-S1PR1-derived CMs. Furthermore, we observed improved cardiac function and reduced fibrosis in a myocardial infarction mouse model induced by left descending artery ligation following transplantation of CMs differentiated more robustly by treatment with S1P or SEW2871. Collectively, S1PR1 activator-treated CMs offer a cost-effective platform for drug discovery and regenerative medicine.
- 2 July 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58  (7) , 2223-2234
Open AccessSphingosine-1-phosphate receptor 1 signaling stimulates human pluripotent stem cell-derived cardiomyocyte differentiation and maturation
The development of human-relevant in vitro cardiac models is essential for evaluating cardiotoxicity and drug efficacy. Although wingless-related integration site signaling-based protocols have enabled cardiomyocyte (CM) differentiation from pluripotent stem cells, issues such as low efficiency, immature phenotype, and variability across cell lines remain to be resolved. Here, we present an improved differentiation strategy that robustly enhances both the efficiency and functional maturity of CMs, comparable to the functional characteristics of human adult myocardial tissue. Although fetal bovine serum enhanced differentiation, we disclosed that the interaction between sphingosine-1-phosphate (S1P) and its receptor S1PR1 is a major contributor. Gene-based and protein-based analyses and electrophysiological analysis via multielectrode array confirmed that activation of S1PR1 using S1P or its agonist SEW2871 increased the generation of spontaneously beating CMs, whereas S1PR1-deficient pluripotent stem cells exhibited impaired differentiation and functional maturity of S1P-S1PR1-derived CMs. Furthermore, we observed improved cardiac function and reduced fibrosis in a myocardial infarction mouse model induced by left descending artery ligation following transplantation of CMs differentiated more robustly by treatment with S1P or SEW2871. Collectively, S1PR1 activator-treated CMs offer a cost-effective platform for drug discovery and regenerative medicine.
- Open Access
- 8 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Author Correction: Chemically-defined and scalable culture system for intestinal stem cells derived from human intestinal organoids
- 8 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessAuthor Correction: Chemically-defined and scalable culture system for intestinal stem cells derived from human intestinal organoids
- Open Access
- 12 February 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58  (2) , 487-500
Drug-induced gastrointestinal toxicity and barrier integrity: cytoskeleton-mediated impairment in a clinically relevant human intestinal epithelium model
Drug-induced gastrointestinal (GI) toxicity is common, dose-limiting and difficult to predict using conventional Caco-2-based assays that lack physiological relevance. Here we evaluate a transepithelial electrical resistance (TEER) assay using nontransformed human intestinal epithelial cells (hIECs), derived from human pluripotent stem cells, which superiorly recapitulated epithelial diversity and polarity as well as intestinal barrier function. Across 17 clinically relevant compounds (cell cycle inhibitors, tyrosine kinase inhibitors and nonsteroidal anti-inflammatory drugs), the hIEC TEER assay outperformed ATP cell viability assays, and the Caco-2 TEER assay (AUC of 0.96 for hIEC TEER, 0.72 for Caco-2 TEER and ≤0.69 for cell viability assays) correlated with integrated GI toxicity scores using a ≥50% TEER reduction cutoff (sensitivity 92%, specificity 100% and accuracy 94%). Drug exposure was quantified by calculating the margin of safety (IC 15 : C max ) and a lumen–surrogate margin of safety for oral agents. For mechanistic insight, transcriptomic analysis using representative chemotherapeutics (paclitaxel and docetaxel) showed the downregulation of cytoskeleton-related pathways, including cytoskeleton in muscle cells, cell adhesion molecules and extracellular matrix–receptor interaction, linking microtubule-targeting chemotherapy to intestinal barrier impairment. This platform provides a robust tool that combines predictive accuracy with the evaluation of cytoskeleton-mediated barrier impairment, enabling the early identification of drug-induced GI toxicity.
- 12 February 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58  (2) , 487-500
Open AccessDrug-induced gastrointestinal toxicity and barrier integrity: cytoskeleton-mediated impairment in a clinically relevant human intestinal epithelium model
Drug-induced gastrointestinal (GI) toxicity is common, dose-limiting and difficult to predict using conventional Caco-2-based assays that lack physiological relevance. Here we evaluate a transepithelial electrical resistance (TEER) assay using nontransformed human intestinal epithelial cells (hIECs), derived from human pluripotent stem cells, which superiorly recapitulated epithelial diversity and polarity as well as intestinal barrier function. Across 17 clinically relevant compounds (cell cycle inhibitors, tyrosine kinase inhibitors and nonsteroidal anti-inflammatory drugs), the hIEC TEER assay outperformed ATP cell viability assays, and the Caco-2 TEER assay (AUC of 0.96 for hIEC TEER, 0.72 for Caco-2 TEER and ≤0.69 for cell viability assays) correlated with integrated GI toxicity scores using a ≥50% TEER reduction cutoff (sensitivity 92%, specificity 100% and accuracy 94%). Drug exposure was quantified by calculating the margin of safety (IC 15 : C max ) and a lumen–surrogate margin of safety for oral agents. For mechanistic insight, transcriptomic analysis using representative chemotherapeutics (paclitaxel and docetaxel) showed the downregulation of cytoskeleton-related pathways, including cytoskeleton in muscle cells, cell adhesion molecules and extracellular matrix–receptor interaction, linking microtubule-targeting chemotherapy to intestinal barrier impairment. This platform provides a robust tool that combines predictive accuracy with the evaluation of cytoskeleton-mediated barrier impairment, enabling the early identification of drug-induced GI toxicity.
- Open Access
- 2 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15  (1) , 1-18
Xenogeneic-free culture of human intestinal stem cells on functional polymer-coated substrates for scalable, clinical-grade stem cell therapy
The need for basement membrane extract (BME) with undefined constituents, such as Matrigel, for intestinal stem cell (ISC) culture in traditional systems poses a significant barrier that must be overcome for the development of clinical-grade, scalable, ready-to-use ISCs. Here, we propose a functional polymer-based xenogeneic-free dish for the culture of intestinal stem cells (XF-DISC), ensuring substantially prolonged maintenance of ISCs derived from 3-dimensional human intestinal organoids (ISCs3D-hIO). XF-DISC enables remarkable expandability, exhibiting a 24-fold increase in cell numbers within 30 days, with long-term maintenance of ISCs3D-hIO for more than 30 consecutive passages (>210 days). In addition, XF-DISC is fully compatible with a cell banking system. Notably, human pluripotent stem cell-derived ISCs3D-hIO cultured on XF-DISC are successfully transplanted into intestinal injury and inflammation mouse models, leading to engraftment and regeneration of damaged mouse intestinal epithelium. As a reliable and scalable xenogeneic-free ISC3D-hIO culture method, XF-DISC is highly promising for the development of regenerative ISC therapy for human intestinal diseases.
- 2 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15  (1) , 1-18
Open AccessXenogeneic-free culture of human intestinal stem cells on functional polymer-coated substrates for scalable, clinical-grade stem cell therapy
The need for basement membrane extract (BME) with undefined constituents, such as Matrigel, for intestinal stem cell (ISC) culture in traditional systems poses a significant barrier that must be overcome for the development of clinical-grade, scalable, ready-to-use ISCs. Here, we propose a functional polymer-based xenogeneic-free dish for the culture of intestinal stem cells (XF-DISC), ensuring substantially prolonged maintenance of ISCs derived from 3-dimensional human intestinal organoids (ISCs3D-hIO). XF-DISC enables remarkable expandability, exhibiting a 24-fold increase in cell numbers within 30 days, with long-term maintenance of ISCs3D-hIO for more than 30 consecutive passages (>210 days). In addition, XF-DISC is fully compatible with a cell banking system. Notably, human pluripotent stem cell-derived ISCs3D-hIO cultured on XF-DISC are successfully transplanted into intestinal injury and inflammation mouse models, leading to engraftment and regeneration of damaged mouse intestinal epithelium. As a reliable and scalable xenogeneic-free ISC3D-hIO culture method, XF-DISC is highly promising for the development of regenerative ISC therapy for human intestinal diseases.
- Open Access
- 26 September 2024
- Published by Elsevier in Biomaterials
- Vol. 314, 122842
Helicobacter pylori VacA-induced mitochondrial damage in the gastric pit cells of the antrum and therapeutic rescue
- 26 September 2024
- Published by Elsevier in Biomaterials
- Vol. 314, 122842
Open AccessHelicobacter pylori VacA-induced mitochondrial damage in the gastric pit cells of the antrum and therapeutic rescue
- Open Access
- 27 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15  (1) , 1-14
Chemically-defined and scalable culture system for intestinal stem cells derived from human intestinal organoids
Three-dimensional human intestinal organoids (hIO) are widely used as a platform for biological and biomedical research. However, reproducibility and challenges for large-scale expansion limit their applicability. Here, we establish a human intestinal stem cell (ISC) culture method expanded under feeder-free and fully defined conditions through selective enrichment of ISC populations (ISC 3D-hIO ) within hIO derived from human pluripotent stem cells. The intrinsic self-organisation property of ISC 3D-hIO , combined with air-liquid interface culture in a minimally defined medium, forces ISC 3D-hIO to differentiate into the intestinal epithelium with cellular diversity, villus-like structure, and barrier integrity. Notably, ISC 3D-hIO is an ideal cell source for gene editing to study ISC biology and transplantation for intestinal diseases. We demonstrate the intestinal epithelium differentiated from ISC 3D-hIO as a model system to study severe acute respiratory syndrome coronavirus 2 viral infection. ISC 3D-hIO culture technology provides a biological tool for use in regenerative medicine and disease modelling.
- 27 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15  (1) , 1-14
Open AccessChemically-defined and scalable culture system for intestinal stem cells derived from human intestinal organoids
Three-dimensional human intestinal organoids (hIO) are widely used as a platform for biological and biomedical research. However, reproducibility and challenges for large-scale expansion limit their applicability. Here, we establish a human intestinal stem cell (ISC) culture method expanded under feeder-free and fully defined conditions through selective enrichment of ISC populations (ISC 3D-hIO ) within hIO derived from human pluripotent stem cells. The intrinsic self-organisation property of ISC 3D-hIO , combined with air-liquid interface culture in a minimally defined medium, forces ISC 3D-hIO to differentiate into the intestinal epithelium with cellular diversity, villus-like structure, and barrier integrity. Notably, ISC 3D-hIO is an ideal cell source for gene editing to study ISC biology and transplantation for intestinal diseases. We demonstrate the intestinal epithelium differentiated from ISC 3D-hIO as a model system to study severe acute respiratory syndrome coronavirus 2 viral infection. ISC 3D-hIO culture technology provides a biological tool for use in regenerative medicine and disease modelling.
- Open Access
- 21 September 2022
- Published by Taylor & Francis in Gut Microbes
- Vol. 14  (1) , 2121580
Limosilactobacillus reuteri DS0384 promotes intestinal epithelial maturation via the postbiotic effect in human intestinal organoids and infant mice
Little is known about the modulatory capacity of the microbiota in early intestinal development. We examined various intestinal models that respond to gut microbial metabolites based on human pluripotent stem cell-derived human intestinal organoids (hIOs): physiologically relevant in vitro fetal-like intestine, intestinal stem cell, and intestinal disease models. We found that a newly isolated Limosilactobacillus reuteri strain DS0384 accelerated maturation of the fetal intestine using 3D hIO with immature fetal characteristics. Comparative metabolomic profiling analysis revealed that the secreted metabolite N-carbamyl glutamic acid (NCG) is involved in the beneficial effect of DS0384 cell-free supernatants on the intestinal maturation of hIOs. Experiments in an intestinal stem cell spheroid model and hIO-based intestinal inflamed model revealed that the cell-free supernatant from DS0384 comprising NCG promoted intestinal stem cell proliferation and was important for intestinal protection against cytokine-induced intestinal epithelial injury. The probiotic properties of DS0384 were also evaluated, including acid and bile tolerance and ability to adhere to human intestinal cells. Seven-day oral administration of DS0384 and cell-free supernatant promoted the intestinal development of newborn mice. Moreover, NCG exerted a protective effect on experimental colitis in mice. These results suggest that DS0384 is a useful agent for probiotic applications and therapeutic treatment for disorders of early gut development and for preventing intestinal barrier dysfunction.
- 21 September 2022
- Published by Taylor & Francis in Gut Microbes
- Vol. 14  (1) , 2121580
Open AccessLimosilactobacillus reuteri DS0384 promotes intestinal epithelial maturation via the postbiotic effect in human intestinal organoids and infant mice
Little is known about the modulatory capacity of the microbiota in early intestinal development. We examined various intestinal models that respond to gut microbial metabolites based on human pluripotent stem cell-derived human intestinal organoids (hIOs): physiologically relevant in vitro fetal-like intestine, intestinal stem cell, and intestinal disease models. We found that a newly isolated Limosilactobacillus reuteri strain DS0384 accelerated maturation of the fetal intestine using 3D hIO with immature fetal characteristics. Comparative metabolomic profiling analysis revealed that the secreted metabolite N-carbamyl glutamic acid (NCG) is involved in the beneficial effect of DS0384 cell-free supernatants on the intestinal maturation of hIOs. Experiments in an intestinal stem cell spheroid model and hIO-based intestinal inflamed model revealed that the cell-free supernatant from DS0384 comprising NCG promoted intestinal stem cell proliferation and was important for intestinal protection against cytokine-induced intestinal epithelial injury. The probiotic properties of DS0384 were also evaluated, including acid and bile tolerance and ability to adhere to human intestinal cells. Seven-day oral administration of DS0384 and cell-free supernatant promoted the intestinal development of newborn mice. Moreover, NCG exerted a protective effect on experimental colitis in mice. These results suggest that DS0384 is a useful agent for probiotic applications and therapeutic treatment for disorders of early gut development and for preventing intestinal barrier dysfunction.
- Open Access
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7  (23) , eabh1586
The development of a functional human small intestinal epithelium model for drug absorption
Directed differentiation of hPSCs and transition from 3D intestinal organoids into functional hIECs.
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7  (23) , eabh1586
Open AccessThe development of a functional human small intestinal epithelium model for drug absorption
Directed differentiation of hPSCs and transition from 3D intestinal organoids into functional hIECs.